Added to YB: 2026-10-08
Pitch date: 2026-10-04
IMRX [bullish]
Immuneering Corporation
-15.97%
current return
Author Info
No bio for this author
Company Info
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Market Cap
$261.4M
Pitch Price
$4.07
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.32
P/E
-4.12
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Immuneering Corporation
IMRX (quick overview): Immuneering, at $4.12, is a precision-oncology bolt-on thesis centered on atebimetinib. The potential value lies in a differentiated dosing approach that may improve MAPK-pathway control, tolerability or combination utility in pancreatic cancer and other RAS-driven tumors. Clinical separation from traditional MEK-inhibitor limitations could make the asset fit companies already selling KRAS drugs, chemotherapy backbones or other oncology combinations; failure to separate would sharply weaken the strategic rationale.
Read full article (1 min)